Image Place holder

Aixa E. Soyano Muller, MD


Specialty: Medical Oncology
Program: Breast Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Aixa Soyano is an Assistant Member in the Department of Breast Oncology. Dr. Soyano received her MD degree from Universidad Central de Venezuela/Escuela de Medicina in Venezuela. She completed an Internal Medicine Residency at Steward Saint Elizabeth’s Medical Center in Boston, Massachusetts. Dr. Soyano recently completed a Hematology Oncology Fellowship at Mayo Clinic in Jacksonville, Florida. Dr. Soyano is interested in the multidisciplinary care of patients of any age and race with breast cancer of any stage and subtype. Her research interest is in the future of oncology related to personalized medicine.

Education & Training

Fellowship:

  • Mayo Clinic - Hematology Oncology

Residency:

  • Steward Saint Elizabeth’s Medical Center - Internal Medicine

Medical School:

  • Universidad Central de Venezuela - MD
Participating Trials

CLINICAL TRIAL 17268
I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2)
Condition: Breast
Intervention:
Open

CLINICAL TRIAL 19117
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer
Condition: Breast
Intervention:
Open

CLINICAL TRIAL 18979
Phase II Open-Label, Randomized Study of PARP inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer
Condition: Breast
Intervention: Atezolizumab (Tecentriq); Olaparib (Lynparza)
Open

CLINICAL TRIAL 19632
A Phase Ib/II, Open-Label, Multicenter,Randomized Umbrella Study Evaluating the Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
Condition: Breast
Intervention: Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab; Cobimetinib; Eribulin Mesylate; Gemzar (gemcitabine); Ipatasertib; Not Applicable; SGN-LIV1A; Xeloda (capecitabine); capecitabine; gemcitabine
Open

CLINICAL TRIAL 19755
A Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination with Intravenous Pembrolizumab Therapy in Patients with Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer
Condition: Breast
Intervention: Pembrolizumab (Keytruda); tavo-EP
Open

CLINICAL TRIAL 18621
A Phase 1/2 Study of Talimogene laherparepvec in Combination with Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Condition: Breast
Intervention: Adriamycin (doxorubicin); Nab-paclitaxel (Abraxane); Talimogene laherparepvec 10^6 PFU (Talimogene Laherparepvec); Talimogene laherparepvec 10^8 PFU (Talimogene Laherparepvec); Taxol (paclitaxel); cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin; paclitaxel
Open

CLINICAL TRIAL 18936
A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients with HER-2 Positive Breast Cancer
Condition: Breast
Intervention: Herceptin (Trastuzumab); Pertuzumab; Taxol (paclitaxel); Trastuzumab; interferon gamma (Actimmune); paclitaxel; rhuMAb HER2 (Trastuzumab)
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Lou Y, Marin-Acevedo JA, Vishnu P, Manochakian R, Dholaria B, Soyano A, Luo Y, Zhang Y, Knutson KL. Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. Immunotherapy. 2019 May;11(7):577-584. Pubmedid: 30943864.
  • Chumsri S, Serie DJ, Li Z, Pogue-Geile KL, Soyano A, Mashadi-Hossein A, Warren SE, Lou Y, Colon-Otero G, Knutson KL, Perez EA, Moreno-Aspitia A, Thompson EA. Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. Clin Cancer Res. 2019 Jul;25(14):4422-4430. Pubmedid: 30808774. Pmcid: PMC6634998.
  • Soyano AE, Baldeo C, Kasi PM. Adjunctive Use of Circulating Tumor DNA Testing in Detecting Pancreas Cancer Recurrence. Front Oncol. 2019 Feb;9:46. Pubmedid: 30788289. Pmcid: PMC6372543.
  • Lou Y, Dholaria B, Soyano A, Hodge D, Cochuyt J, Manochakian R, Ko SJ, Thomas M, Johnson MM, Patel NM, Miller RC, Adjei AA, Ailawadhi S. Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Med. 2018 Oct;7(10):4932-4942. Pubmedid: 30175515. Pmcid: PMC6198232.
  • Dholaria BR, Hammond WA, Roy V, Sher T, Vishnu P, Soyano A, Finn LE, Tun H. Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience. Leuk Lymphoma. 2018 Nov;59(11):2727-2730. Pubmedid: 29566563.
  • Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018 Mar;11(1):39. Pubmedid: 29544515. Pmcid: PMC5856308.
  • Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018 Jan;11(1):8. Pubmedid: 29329556. Pmcid: PMC5767051.
  • Soyano AE, Baldeo C, Kasi PM. BRCA Mutation and Its Association With Colorectal Cancer. Clin Colorectal Cancer. 2018 Dec;17(4):e647-e650. Pubmedid: 30033118.
  • Soyano AE, Reynolds G, Moreno-Aspitia A, Chumsri S. Rifaximin for Pertuzumab-Related GI Toxicities. Front Oncol. 2017 Aug;7:168. Pubmedid: 28848707. Pmcid: PMC5550690.
  • Soyano AE, Kassi M, Kasi PM. Neuroendocrine Tumor Involving the Epicardium. Case Rep Oncol. 10(3):1144-1149. Pubmedid: 29430241. Pmcid: PMC5803682.